Imexpharm (STC:IMP) Ending Cash Position: ₫75,791 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STC:IMP Imexpharm Corp STC:IMP
98 GF Score
Price ₫39,100.00
GF Value ₫52,924.93
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Imexpharm Ending Cash Position?

Imexpharm STC:IMP -2.98% 98 Ending Cash Position is ₫75,791 Mil as of Mar. 2026. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫52,924.93 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Imexpharm's Ending Cash Position for the quarter that ended in Mar. 2026 was ₫75,791 Mil.

Imexpharm's quarterly Ending Cash Position increased from Sep. 2025 (₫173,644 Mil) to Dec. 2025 (₫189,193 Mil) but then declined from Dec. 2025 (₫189,193 Mil) to Mar. 2026 (₫75,791 Mil).

Imexpharm's annual Ending Cash Position increased from Dec. 2023 (₫106,201 Mil) to Dec. 2024 (₫161,983 Mil) and increased from Dec. 2024 (₫161,983 Mil) to Dec. 2025 (₫189,193 Mil).

Imexpharm Ending Cash Position Related Terms

Imexpharm Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Imexpharm's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imexpharm Ending Cash Position Chart

Imexpharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 271,272.87 178,845.07 106,200.57 161,983.32 189,193.29

Imexpharm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 303,022.33 261,694.10 173,643.51 189,193.29 75,791.00
STC:IMP
98GF Score
Imexpharm Corp STC:IMP
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imexpharm Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Imexpharm's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=161983.379+27209.909
=189,193

Imexpharm's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=189537.667+-113746.666
=75,791

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₫75,791 Mil mean?
Imexpharm (STC:IMP) has a Ending Cash Position of ₫75,791 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Imexpharm and its competitors.
Is Imexpharm's Ending Cash Position too high?
Imexpharm's current Ending Cash Position is ₫75,791 Mil. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Ending Cash Position compare to ZTS and UTHR?
Imexpharm's Ending Cash Position of ₫75,791 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Imexpharm and its competitors. Imexpharm's current Ending Cash Position is ₫75,791 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫52,924.93, compared to a current price of ₫39,100.00 — trading 26.1% below its estimated fair value. The current Ending Cash Position is ₫75,791 Mil. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Ending Cash Position is ₫75,791 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫39,100.00 is trading 26.1% below its estimated GF Value™ of ₫52,924.93. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • Ending Cash Position: ₫75,791 Mil
  • GF Value™: ₫52,924.93 vs. price of ₫39,100.00 (26.1% below fair value)
  • GF Score™: 98/100 with 2 warning signs

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score

Get the complete analysis for STC:IMP

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫39,100.00
Price
₫52,924.93
GF Value